Pfizer
235 East 42nd Street
New York, NY 10017
United States
Tel: (212) 733-2323
Website: https://www.pfizer.com/
5353 articles about Pfizer
-
After a brief slump, interest in ADCs is at an all-time high, highlighted by a handful of recent multi-million- and billion-dollar acquisitions. -
Arvinas and Pfizer Announce Upcoming Vepdegestrant (ARV-471) Poster Presentations at the 2023 European Society for Medical Oncology (ESMO) Breast Cancer Annual Congress
5/8/2023
Arvinas, Inc. (Nasdaq: ARVN) and Pfizer Inc. (NYSE: PFE) today announced they will present updated data related to vepdegestrant (ARV-471) at the 2023 European Society for Medical Oncology (ESMO) Breast Cancer Annual Congress.
-
Idea Pharma’s annual index reveals key drivers and metrics for large companies. AstraZeneca and Pfizer remain in the top positions this year for invention and innovation, respectively. -
As the COVID-19 market dries up, Moderna looks to FDA approval of its other vaccines including a 2024 commercial launch of its investigational RSV vaccine for older adults.
-
The company’s pipeline changes come as it weathered a nearly 30% decline in first-quarter revenues due to a slowdown in its COVID-19 business. -
Pfizer Receives AUA Health Science Award
4/29/2023
The American Urological Association announced that Pfizer Oncology is the recipient of the 2023 Health Science Award for its outstanding support of the educational, scientific and research goals of the AUA and the Urology Care Foundation in urologic cancer.
-
XTANDI® (enzalutamide) plus Leuprolide Reduced the Risk of Metastasis by 58% in Non-Metastatic Hormone-Sensitive Prostate Cancer versus Placebo plus Leuprolide
4/29/2023
Astellas Pharma Inc. and Pfizer Inc. announced that XTANDI® plus leuprolide significantly reduced the risk of metastasis or death by 58% versus placebo plus leuprolide, as assessed by the primary endpoint of metastasis-free survival, in men with non-metastatic hormone-sensitive prostate cancer with high-risk biochemical recurrence.
-
Prevnar 20 is indicated for the prevention of invasive pneumococcal disease and otitis media in children. -
U.S. FDA Approves PREVNAR 20®, Pfizer’s 20-valent Pneumococcal Conjugate Vaccine for Infants and Children
4/27/2023
Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved PREVNAR 20® (20-valent Pneumococcal Conjugate Vaccine) for the prevention of invasive pneumococcal disease (IPD) caused by the 20 Streptococcus pneumoniae (pneumococcal) serotypes contained in the vaccine in infants and children six weeks through 17 years of age.
-
Pfizer Declares Second-Quarter 2023 Dividend
4/26/2023
Pfizer Inc. announced that its board of directors declared a $0.41 second-quarter 2023 dividend on the company’s common stock, payable June 9, 2023, to holders of the Common Stock of record at the close of business on May 12, 2023.
-
The lawsuit, brought by Arbutus Biopharma, marks the latest legal action in an ongoing battle for intellectual property underlying mRNA vaccines for COVID-19.
-
Phase III data for Pfizer's respiratory syncytial virus vaccine candidate showed high levels of protection for older adults and infants. -
FDA Accepts Pfizer’s Supplemental New Drug Applications for BRAFTOVI + MEKTOVI
4/4/2023
Pfizer Inc. announced that the U.S. Food and Drug Administration has accepted for review the Supplemental New Drug Applications for BRAFTOVI® + MEKTOVI® for patients with metastatic non-small cell lung cancer with a BRAF V600E mutation, as detected by an FDA-approved test.
-
Merck KGaA, Darmstadt, Germany Strengthens Oncology Franchise by Securing Exclusive Worldwide Rights to Anti PD-L1 Antibody BAVENCIO® (avelumab)
3/27/2023
Merck KGaA, Darmstadt, Germany regains exclusive worldwide rights to develop, manufacture and commercialize BAVENCIO from Pfizer.
-
Flare Therapeutics Announces Oversubscribed $123 Million Series B Financing
3/22/2023
Flare Therapeutics Inc. announced a $123 million Series B financing co-led by GordonMD® Global Investments LP and Pfizer Ventures, with participation from existing investors Boxer Capital, Casdin Capital, Eventide Asset Management, Invus Financial Advisors, Nextech Invest and Third Rock Ventures and new investors Agent Capital, Eli Lilly and Company, Memorial Sloan Kettering Cancer Center, Novartis, Pavilion Capital and ShangBay Capital.
-
As demand for biotech talent increases, the need to offer competitive pay to the average employee puts financial pressure on companies to increase CEO pay as well. -
Pfizer and Astellas announced positive topline Phase III results Thursday for Xtandi plus leuprolide in non-metastatic castration-sensitive prostate cancer. -
Phase 3 Study Shows XTANDI® (enzalutamide) plus Leuprolide Significantly Improves Metastasis-Free Survival in Men with Non-Metastatic Prostate Cancer
3/16/2023
Pfizer Inc. and Astellas Pharma Inc. announced positive topline results from the Phase 3 EMBARK trial evaluating XTANDI® in men with non-metastatic hormone-sensitive prostate cancer with high-risk biochemical recurrence.
-
FDA Advisory Committee Votes in Support of Favorable Benefit-Risk Profile for Pfizer’s PAXLOVID™
3/16/2023
Pfizer Inc. announced that the U.S. Food and Drug Administration’s Antimicrobial Drugs Advisory Committee voted 16 to 1 that available data support the safety and effectiveness of PAXLOVID™ for the treatment of mild-to-moderate COVID-19 in adult patients who are at high risk for progression to severe illness.
-
Pfizer will acquire the Seattle-based antibody-drug conjugate leader in a $43 billion deal expected to close late in 2023 or early 2024.